NeoGenomics Inc. Launches c-MET CDx Assay for Rapid Treatment Guidance in Advanced Non-Small Cell Lung Cancer

Reuters

05-22

<a href="https://laohu8.com/S/NEO">NeoGenomics</a> Inc. Launches c-MET CDx Assay for Rapid Treatment Guidance in Advanced Non-Small Cell Lung Cancer

NeoGenomics, Inc., a prominent provider of oncology testing services, has announced the commercial launch of its c-MET CDx assay for advanced non-small cell lung cancer (NSCLC). This companion diagnostic immunohistochemistry $(IHC)$ assay is designed to assist in the treatment selection for NSCLC patients by detecting c-Met protein overexpression, a biomarker found in up to 50% of advanced NSCLC cases. The assay delivers rapid results within 48 hours, aiding in timely clinical decision-making. It supports patient eligibility for newly approved targeted therapies, including EMRELIS™ (telisotuzumab vedotin-tllv), approved by the U.S. FDA for adults with previously treated advanced NSCLC exhibiting high c-MET protein overexpression. This launch expands NeoGenomics' comprehensive NSCLC testing portfolio, aligning with evolving precision cancer care standards. For further details, visit NeoGenomics' official website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250522491999) on May 22, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2537481459"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537481459\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2537481459?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-22 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537481459","market":"nz","top_or_hot":-1,"title":"NeoGenomics Inc. Launches c-MET CDx Assay for Rapid Treatment Guidance in Advanced Non-Small Cell Lung Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NEO\">NeoGenomics</a> Inc. Launches c-MET CDx Assay for Rapid Treatment Guidance in Advanced Non-Small Cell Lung Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeoGenomics, Inc., a prominent provider of oncology testing services, has announced the commercial launch of its c-MET CDx assay for advanced non-small cell lung cancer (NSCLC). This companion diagnostic immunohistochemistry <a href=\"https://laohu8.com/S/IHC\">$(IHC)$</a> assay is designed to assist in the treatment selection for NSCLC patients by detecting c-Met protein overexpression, a biomarker found in up to 50% of advanced NSCLC cases. The assay delivers rapid results within 48 hours, aiding in timely clinical decision-making. It supports patient eligibility for newly approved targeted therapies, including EMRELIS™ (telisotuzumab vedotin-tllv), approved by the U.S. FDA for adults with previously treated advanced NSCLC exhibiting high c-MET protein overexpression. This launch expands NeoGenomics' comprehensive NSCLC testing portfolio, aligning with evolving precision cancer care standards. For further details, visit NeoGenomics' official website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250522491999) on May 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeoGenomics Inc. Launches c-MET CDx Assay for Rapid Treatment Guidance in Advanced Non-Small Cell Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeoGenomics Inc. Launches c-MET CDx Assay for Rapid Treatment Guidance in Advanced Non-Small Cell Lung Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-22 19:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NEO\">NeoGenomics</a> Inc. Launches c-MET CDx Assay for Rapid Treatment Guidance in Advanced Non-Small Cell Lung Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeoGenomics, Inc., a prominent provider of oncology testing services, has announced the commercial launch of its c-MET CDx assay for advanced non-small cell lung cancer (NSCLC). This companion diagnostic immunohistochemistry <a href=\"https://laohu8.com/S/IHC\">$(IHC)$</a> assay is designed to assist in the treatment selection for NSCLC patients by detecting c-Met protein overexpression, a biomarker found in up to 50% of advanced NSCLC cases. The assay delivers rapid results within 48 hours, aiding in timely clinical decision-making. It supports patient eligibility for newly approved targeted therapies, including EMRELIS™ (telisotuzumab vedotin-tllv), approved by the U.S. FDA for adults with previously treated advanced NSCLC exhibiting high c-MET protein overexpression. This launch expands NeoGenomics' comprehensive NSCLC testing portfolio, aligning with evolving precision cancer care standards. For further details, visit NeoGenomics' official website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250522491999) on May 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL9m7sp3:1","article_id":"2537481459","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537481459","pubTimestamp":1747912212,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire  on May 22, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"NeoGenomics Inc.推出用于晚期非小细胞肺癌快速治疗指导的c-MET CDx检测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEO":0.9},"content_text":"NeoGenomics Inc. Launches c-MET CDx Assay for Rapid Treatment Guidance in Advanced Non-Small Cell Lung Cancer\n    \n\n        NeoGenomics, Inc., a prominent provider of oncology testing services, has announced the commercial launch of its c-MET CDx assay for advanced non-small cell lung cancer (NSCLC). This companion diagnostic immunohistochemistry $(IHC)$ assay is designed to assist in the treatment selection for NSCLC patients by detecting c-Met protein overexpression, a biomarker found in up to 50% of advanced NSCLC cases. The assay delivers rapid results within 48 hours, aiding in timely clinical decision-making. It supports patient eligibility for newly approved targeted therapies, including EMRELIS™ (telisotuzumab vedotin-tllv), approved by the U.S. FDA for adults with previously treated advanced NSCLC exhibiting high c-MET protein overexpression. This launch expands NeoGenomics' comprehensive NSCLC testing portfolio, aligning with evolving precision cancer care standards. For further details, visit NeoGenomics' official website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250522491999) on May 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}